Margi McLoughlin is an Executive Director in Worldwide Business Development (WWBD) at Pfizer based in South San Francisco, CA. Margi currently works with Pfizer’s Worldwide R&D (WRD) organization and Pfizer Venture Investments to manage Pfizer’s R&D Innovate (RDI) initiative invest in companies working in areas aligned with the future directions of WR&D. In RDI, she serves on the boards of 4D Molecular Therapeutics, Adapsyn, BioAtla and Cortexyme. Through these investments, she works with the companies and WRD leadership to help advance products and technologies of value to the pharmaceutical industry.
Margi held a position in Discovery Research at Mallinckrodt Medical, developing diagnostic pharmaceuticals for nuclear medicine, MR and X-ray imaging. After five years in the laboratory, Margi spent two years in Technology Planning at Mallinckrodt Medical, where she supported internal R&D through outside alliances. In 1999, she moved to Yale University where she worked as Associate Director in the Office of Cooperative Research. Since joining Pfizer in 2001, she has had roles of increasing responsibility in WWBD and has had a significant role in defining Pfizer’s Centers for Therapeutic Innovation and led transactions with multiple biotech companies (Ablexis, Gliknik, Excaliard, etc…).